Backgroundand study aims:Hepatitis C virus (HCV) is the main leading cause of liver disease in ‎Egypt. A new era of HCV treatment has been started with the evolution ‎of direct acting antiviral agents. Sofosbuvir (SOF)-based therapy was ‎introduced by the Egyptian ministry of health in 2014 in an attempt to ‎decrease disease burden. We aimed to evaluate efficacy and safety of ‎Sofosbuvir-based regimens in HCV Egyptian patients with compensated ‎liver disease‎.
Patients and Method:‎This study was conducted in National Liver Institute, Menoufia‎University, Egypt. Seven hundred patients out of seven hundred fifty-‎eight chronic HCV patients with compensated liver disease who met the ‎inclusion criteria were included. According to treatment regimen patients ‎were divided to 4 groups; group 1 received Sofosbuvir (SOF), ‎Pegylated interferon (PEG-IFN) plus ribavirin (RBV), group 2 received ‎SOF plus RBV, group 3 received SOF and Simeprevir± RBV, group 4 ‎received SOF and Daclatasvir ±RBV‎.‎
Results:The overall SVR was 90.9%, 81.5%, 95% and 98% in groups 1, 2, 3, ‎and 4 respectively. SVR in patients with liver cirrhosis was 90.56, ‎‎79.16, 95 and 96% in the 4 groups respectively. In treatment ‎experienced patients, SVR was 86.8% in group 1, 78.3% in group 2, ‎‎100% in group 3 and 86.7% in group 4‎‎‎‎.
Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin is the safest ‎andmost effective SOF-based regimen in treatment of HCV Egyptian ‎patients with compensated liver disease‎‎‎‎.